Mirum Pharmaceuticals, Inc. Repayments of Convertible Debt
Mirum Pharmaceuticals, Inc. (MIRM) reported Repayments of Convertible Debt of $474.37 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfConvertibleDebt · last filed 2026-08-05
- 2026-06-30: Repayments of Convertible Debt 6 month $474.37M.
- 2025-06-30: Repayments of Convertible Debt 6 month $0.00.
| Period end | Repayments of Convertible Debt 6 month |
|---|---|
| 2026-06-30 | $474.37M 10-Q · filed 2026-08-05 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |